- Home
- BRTX vs TULP Comparison
BRTX vs TULP Comparison
Compare BRTX & TULP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRTX | TULP |
|---|---|---|
| Founded | 1997 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Farming/Seeds/Milling |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 8.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BRTX | TULP |
|---|---|---|
| Price | $0.26 | $4.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 827.5K | 112.7K |
| Earning Date | 03-26-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.70 |
| Revenue | $383,400.00 | ★ $69,769,000.00 |
| Revenue This Year | $112.14 | N/A |
| Revenue Next Year | $139.81 | N/A |
| P/E Ratio | ★ N/A | $6.36 |
| Revenue Growth | 1.70 | ★ 121.91 |
| 52 Week Low | $0.22 | $3.11 |
| 52 Week High | $2.50 | $6.19 |
Technical Indicators
Market Signals| Indicator | BRTX | TULP |
|---|---|---|
| Relative Strength Index (RSI) | 11.42 | N/A |
| Support Level | $0.22 | N/A |
| Resistance Level | $1.13 | N/A |
| Average True Range (ATR) | 0.09 | 0.00 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 3.22 | 0.00 |
Price Performance
Historical ComparisonAbout BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.